



600 University Street, Suite 3600  
 Seattle, Washington 98101  
 main 206.624.0900  
 fax 206.386.7500  
 www.stoel.com

Name:	Fax No.	Company/Firm	Phone No.
TO: David S. Romeo	(571) 273-0890	USPTO	

Name:	Sender's Direct Dial:	Sender's Direct Email:
FROM: Samuel E. Webb	(206) 386-7683	sewebb@stoel.com

Client: 38263	Matter: 19
---------------	------------

Date: May 12, 2009

No. of Pages (including this cover): 5

Originals Not Forwarded Unless Checked:  First Class Mail  Overnight Delivery  Hand Delivery

**In case of error, call the fax operator at (206) 386-7506.**

*This facsimile may contain confidential information that is protected by the attorney-client or work product privilege. If the reader of this message is not the intended recipient or an employee responsible for delivering the facsimile, please do not distribute this facsimile, notify us immediately by telephone, and return this facsimile by mail. Thank you.*

**COMMENTS:**

Re Application No. 10/519,342 for Li, et al.

**PROPOSED DRAFT FOR INTERVIEW DISCUSSION PURPOSES ONLY**  
**DO NOT ENTER**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Appl. No. : 10/519,342 Confirmation No. 2504  
Applicant : Li et al.  
Title : METHODS AND COMPOSITIONS FOR  
MANIPULATING THE GUIDED NAVIGATION OF  
ENDOTHELIAL TUBES DURING ANGIOGENESIS  
Filed : September 21, 2005  
TC/A.U. : 1647  
Examiner : David S. Romeo  
Docket No. : 38263/19  
Customer No. : 32642

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**PROPOSED DRAFT AMENDMENT**

Dear Sir:

In response to the Office Action of February 19, 2009, please amend the above-identified application as follows:

The **Listing of Claims** begins on page 2 of this paper.

Appl. No.10/519,342  
DRAFT Amdt. dated May 12, 2009  
FOR DISCUSSION PURPOSES ONLY – DO NOT ENTER

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claim in the application:

**Listing of Claims:**

Claims 1 through 6 canceled.

7. (Currently Amended) A method of preventing guided navigation of endothelial tubes during angiogenesis to a target cell mass inhibiting migration human microvascular endothelial cells (HMVECs) expressing a native Robo-4 receptor, wherein said endothelial tubes express a Robo-4 receptor, the method comprising activating said Robo-4 receptor, wherein activating said Robo-4 receptor exposing said HMVECs to a Slit ligand, wherein exposing said HMVECs to said Slit ligand inhibits the guided navigation of the endothelial tubes toward the target cell mass migration of said HMVECs.

8. (Currently Amended) The method of claim 7, wherein activating said Robo-4 receptor comprises providing a ligand capable of activating said Robo-4 receptor and exposing said endothelial tubes to the ligand, wherein said exposure of said endothelial tubes to said ligand inhibits the guided navigation of the endothelial tubes toward the target cell mass exposing said HMVECs to a Slit ligand comprises exposing said HMVECs to a Slit2 ligand.

9. (Currently Amended) The method of claim 8, wherein providing a ligand capable of activating said Robo-4 receptor comprises providing a Slit exposing said HMVECs to a Slit2 ligand comprises exposing said HMVECs to a human Slit2 ligand or a fragment thereof.

Claims 10 through 18 canceled.

Page 2 of 4

K:\NaviGen\1912A095734.tmp

Appl. No.10/519,342  
DRAFT Amdt. dated May 12, 2009  
FOR DISCUSSION PURPOSES ONLY – DO NOT ENTER

19. (Currently Amended) A method of preventing angiogenesis in endothelium tissue-expressing Robo-4 receptor, the method comprising, activating said Robo-4 receptor, wherein activating said Robo-4 receptor inhibits migration of endothelial cells inhibiting migration of HMVECs expressing a native Robo-4 receptor, wherein inhibiting migration of said HMVECs comprises providing a Slit ligand and exposing said HMVECs to said Slit ligand such that migration of said HMVECs is inhibited

20. (Currently Amended) The method of claim 19, wherein activating said Robo-4 receptor comprises providing a ligand capable of activating said Robo-4 receptor and exposing the endothelium tissue to the ligand, wherein said exposure of said endothelium tissue to said ligand inhibits migration of endothelial cells providing a Slit ligand comprises providing a Slit2 ligand.

21. (Currently Amended) The method of claim 20, wherein providing a ligand capable of activating said Robo-4 receptor providing a Slit2 ligand comprises providing a Slit ligand providing a human Slit2 ligand or a fragment thereof.

Claim 22 canceled.

Appl. No.10/519,342  
DRAFT Amdt. dated May 12, 2009  
FOR DISCUSSION PURPOSES ONLY - DO NOT ENTER

Respectfully submitted,

---

Samuel E. Webb  
Reg. No. 44,394  
Attorney for Applicant

Date: May 12, 2009

STOEL RIVES LLP  
600 University Street, Suite 3600  
Seattle, WA 98101  
Telephone: (206) 386-7683  
Facsimile: (206) 386-7500